Topic updates

06 February 2026
Evaluation results are now expected to be communicated during the third week of February 2026.

26 September 2025
Call HORIZON-HLTH-2025-01 closed on 16 September 2025. 749 proposals were submitted. The breakdown per topic is:

HORIZON-HLTH-2025-01-TOOL-05: 25 proposals

Evaluation results are expected to be communicated on Wednesday 21 January 2026 at the earliest.

10 June 2025
Please note that due to a technical issue, during the first days of publication of this call, the topic page did not display the description of the corresponding destination. This problem is now solved. In addition to the information published in the topic page, you can always find a full description of the relevant destination in the Work Programme 2025 part for "Health". Please select from the work programme the destination relevant to your topic and take into account the description and expected impacts of that destination for the preparation of your proposal.

Boosting the translation of biotech research into innovative health therapies

TOPIC ID: HORIZON-HLTH-2025-01-TOOL-05

Type of grant: Call for proposals

General information

Programme:

Call: Cluster 1 - Health (Single stage - 2025) (HORIZON-HLTH-2025-01)

Type of action: HORIZON-RIA HORIZON Research and Innovation Actions

Type of MGA: HORIZON Action Grant Budget-Based [HORIZON-AG]

Status: Forthcoming

Deadline model: single-stage

Planned Opening Date: 22 May 2025

Deadline dates: 16 September 2025 17:00 (Brussels time)

Topic description

Expected Outcome:

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Developing and using new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim to deliver results directed towards and contributing to all the following expected outcomes:

• Healthcare providers, researchers and patients get faster access to innovative therapies.
• The European Union benefits from more clinical trials being conducted with new biotech therapeutic approaches.
• The competitiveness of small and medium-sized enterprises (SMEs) from the EU and Associated Countries within the health biotech sector is strengthened.

Scope:

The Commission Communication 'Building the future with nature: Boosting Biotechnology and Biomanufacturing in the EU' ^[1] has recently identified research and technology transfer to the market as a major challenge for the biotechnology sector. This topic aims to speed up the development of innovative biotechnology-based therapies by supporting the initial phases of clinical research. SMEs play a key role in the EU's potential to innovate, with most biotechnology-derived drugs in development being progressed by SMEs and small biotech companies. However, transitioning from drug discovery and development stages to approved products requires substantial investment and sufficient resources in different areas (e.g., manufacturing, clinical trial management, regulatory affairs, etc.), with the time needed for clinical development often exceeding 10 years^[2]. This topic targets collaborative multidisciplinary consortia of SMEs, academics, clinicians and research organisations bringing together the necessary expertise to launch the clinical development of novel biotechnology-derived therapeutics. Collaboration with the relevant European research infrastructures is encouraged. This topic does not address the full clinical development needed to bring products to market but aims to support the critical transition phase from preclinical to clinical development by supporting the early clinical phases. A non-exhaustive list of biotechnology-derived therapies in scope include monoclonal antibodies, (therapeutic) vaccines, recombinant biomolecules, Advanced Therapy Medicinal Products (ATMPs), nano-based drugs, RNA therapies etc. Whole blood, blood components and other substances of human origin are not within the scope of this topic.

Proposals submitted under this topic should include all the following elements:

• A Clinical study either phase I, II or I/II depending on the appropriate stage of development.
• The proposal should convincingly demonstrate a significant economic potential of the final product(s) for the Single Market.
• A clearly defined exploitation plan, with a detailed proposed route to commercialisation, description of the intellectual property ownership and benefit for the SME(s). The plan should include an anti-shelving strategy, commercial forecasts for the product sales & revenue, and strategies for follow-up financing as well as market authorisation. The exploitation strategy should envisage a first deployment in the EU.
• Justification of the patient populations that will benefit directly from the development of the therapies. Clinical indications where potentially large patient populations could benefit will be favoured.

The maximum project duration should not exceed four years.

Applicants should provide details of their clinical studies^[3] in the dedicated annex using the template provided in the submission system. As proposals under this topic are expected to include clinical studies, the use of the template is strongly encouraged.

[1] https://research-and-innovation.ec.europa.eu/document/download/47554adc-dffc-411b-8cd6-b52417514cb3_en

[2] https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf

[3] Please note that the definition of clinical studies (see introduction to this work programme part) is broad and it is recommended that you review it thoroughly before submitting your application.

Start submission

The submission system is planned to be opened on the date stated on the topic header.

Get support

Please read carefully all provisions below before the preparation of your application.

Online Manual is your guide on the procedures from proposal submission to managing your grant.

Horizon Europe Programme Guide contains the detailed guidance to the structure, budget and political priorities of Horizon Europe.

Funding & Tenders Portal FAQ – find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.

Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.

National Contact Points (NCPs) – get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (‘third-countries’).

Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.

IT Helpdesk – contact the Funding & Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.

European IPR Helpdesk assists you on intellectual property issues.

CEN-CENELEC Research Helpdesk and ETSI Research Helpdesk – the European Standards Organisations advise you how to tackle standardisation in your project proposal.

The European Charter for Researchers and the Code of Conduct for their recruitment – consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.

Partner Search help you find a partner organisation for your proposal.